Tag: meet

Pfizer&#39s Phase III renal cell carcinoma trial fails to meet major endpoint The mixture of bevacizumab and IFN-alpha-2a is authorized as first-line treatment for advanced RCC and clinical supplies of both of these drugs in this trial were provided through an agreement with Roche. … The inhibition of mTOR also reduces … Study far more…